lifestyle.fictiontalk.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Prelude Therapeutics, Incorporated
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
April 20, 2026
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
April 20, 2026
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
April 15, 2026
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
March 17, 2026
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
March 10, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
February 3, 2026